State of New Jersey Common Pension Fund D Decreases Stock Holdings in Bruker Corporation $BRKR

State of New Jersey Common Pension Fund D decreased its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 19.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 50,559 shares of the medical research company’s stock after selling 12,372 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Bruker were worth $2,382,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. M&T Bank Corp purchased a new stake in shares of Bruker in the fourth quarter valued at $479,000. Comerica Bank lifted its holdings in shares of Bruker by 62.6% in the 4th quarter. Comerica Bank now owns 50,153 shares of the medical research company’s stock worth $2,363,000 after acquiring an additional 19,317 shares during the last quarter. Cornerstone Investment Partners LLC lifted its holdings in shares of Bruker by 11.0% in the 4th quarter. Cornerstone Investment Partners LLC now owns 11,473 shares of the medical research company’s stock worth $540,000 after acquiring an additional 1,136 shares during the last quarter. Peregrine Capital Management LLC lifted its holdings in shares of Bruker by 27,660.8% in the 4th quarter. Peregrine Capital Management LLC now owns 138,804 shares of the medical research company’s stock worth $6,539,000 after acquiring an additional 138,304 shares during the last quarter. Finally, Legacy Capital Group California Inc. lifted its holdings in shares of Bruker by 2.6% in the 4th quarter. Legacy Capital Group California Inc. now owns 22,195 shares of the medical research company’s stock worth $1,046,000 after acquiring an additional 567 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Up 3.4%

Shares of BRKR opened at $43.73 on Friday. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $56.22. The company has a 50-day moving average of $37.26 and a 200 day moving average of $42.06. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of -182.21, a PEG ratio of 2.53 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.87.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million during the quarter, compared to analyst estimates of $795.62 million. During the same quarter last year, the business posted $0.47 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a dividend of $0.05 per share. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is presently -133.33%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BRKR shares. Citigroup raised their target price on shares of Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, April 24th. Guggenheim lowered their target price on shares of Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a report on Monday, March 30th. Barclays raised their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, TD Cowen raised their target price on shares of Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bruker has a consensus rating of “Hold” and an average target price of $50.15.

Key Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 revenue and EPS topped estimates — Bruker reported $823.4M in revenue and $0.31 EPS versus consensus ~$0.23, giving investors a near‑term catalyst and validating demand in parts of the business. BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
• Positive Sentiment: Management highlighted strength in Europe and robust BSI (biopharma services & instruments) bookings that should help future revenue visibility even as some organic sales softened. Bruker (BRKR) Q1 2026 Earnings Transcript
• Neutral Sentiment: FY‑2026 EPS guidance was set at $2.10–$2.15, essentially in line with the ~2.12 consensus; revenue guidance is centered around $3.6B — this reduces surprise potential but gives a clear framework for the year. Bruker Press Release / FY2026 Guidance
• Neutral Sentiment: Company released the earnings slide deck and call presentation, providing detail on segment trends, backlog and margin drivers for investors doing deeper modeling. Bruker Corporation 2026 Q1 – Results – Earnings Call Presentation
• Negative Sentiment: Profitability pressure: margins declined, net margin was slightly negative (-0.25%), and EPS is down vs. prior year ($0.47 → $0.31). Softer organic sales and margin headwinds are a near‑term concern that could cap upside until margin recovery is clearer. Bruker: Q1 Earnings Snapshot

Insiders Place Their Bets

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 27.20% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.